AstraZeneca invests $2 billion in Summit Therapeutics for 12% stake

By Public Technologies
  • AstraZeneca agreed to invest USD 2 billion in newly issued equity in Summit Therapeutics to accelerate ivonescimab development.
  • Purchase covers about 109,000 preferred shares convertible into common stock at a 1:1,000 ratio.
  • Post-closing stake equals about 12.0% of Summit common stock outstanding, or about 10.6% on a fully diluted basis.
  • Closing is expected within one week; any later conversion to common stock requires customary regulatory clearances.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AstraZeneca plc published the original content used to generate this news brief on September 28, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.